|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


* Division of Clinical Chemistry, Department of Laboratory
Medicine, Karolinska University Hospital, Huddinge, Sweden
Department of Clinical Pharmacology, University of
Bonn, Bonn, Germany
Department of Surgical
Sciences, Karolinska University Hospital, Solna, Sweden
Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M500024-JLR200
1 To whom correspondence should be addressed. e-mail: Ingemar.Bjorkhem{at}karolinska.se
| ABSTRACT |
|---|
|
|
|---|
The distribution of 27-hydroxycholesterol in human brain was found to be consistent with an extracerebral origin, with a concentration gradient from the white to the gray matter
Supplementary key words bloodbrain barrier brain cholesterol oxysterol 24S-hydroxycholesterol
| INTRODUCTION |
|---|
|
|
|---|
25 mg/24 h, and the flux of 24S-hydroxycholesterol from the brain to the
liver to
7 mg/24 h. The latter mechanism seems to be the quantitatively most
important for elimination of cholesterol from the brain in both man and
experimental animals (3,
79). We have shown that most of the flux of
24S-hydroxycholesterol from the brain represents a direct transport over the
bloodbrain barrier, whereas only a minor part is eliminated through
cerebrospinal fluid. Cholesterol 24-hydroxylase (CYP46A1), the enzyme responsible for formation of 24S-hydroxycholesterol, is almost exclusively located in the brain (9), and as a consequence, almost all 24S-hydroxycholesterol present in the human circulation originates from this organ (3). On the other hand, the enzyme responsible for formation of 27-hydroxycholesterol, sterol 27-hydroxylase (CYP27A1), is present in most organs and tissues. Although there is some expression of CYP27A1 in the brain, the levels of the enzymatic product, 27-hydroxycholesterol, in brain tissues are low, only 1020% those of 24S-hydroxycholesterol (4). Recently, evidence has been presented that there may be some passage of 27-hydroxycholesterol from the circulation into the brain. In a metabolic experiment in which deuterium-labeled cholesterol was infused into a healthy volunteer, deuterium-labeled 27-hydroxycholesterol could be detected in the cerebrospinal fluid (10). In accordance with the demonstrated inability of circulating cholesterol to pass the bloodbrain barrier, no detectable deuterium enrichment of cerebrospinal fluid cholesterol or 24S-hydroxycholesterol was observed. Moreover a significant correlation was found between the levels of 27-hydroxycholesterol in cerebrospinal fluid and in the circulation of a population of human subjects (11).
In the present work,
we tested the hypothesis that there is a significant net flux of
27-hydroxycholesterol from the circulation into the brain by measuring the
concentration of this oxysterol in the internal jugular vein and in the brachial
artery of healthy volunteers. If there is a net uptake of this oxysterol in the
brain, higher levels would be expected in an artery than in the internal jugular
vein. For reasons of validation and comparison, respectively, we also measured
the levels of 24S-hydroxycholesterol and 7
-hydroxycholesterol. According to
our previous work (3, 4), the levels of 24S-hydroxycholesterol
would be expected to be higher in the vein than in the artery, whereas
7
-hydroxycholesterol would be expected to be present at the same
concentration in both the vein and the artery. As with steroid hormones, a
possible uptake of oxysterols from the circulation into the brain would be
expected to occur with the steroid in the free form. However, most oxysterols in
the circulation are esterified.
In view of these concerns, we made one initial study on 12 healthy volunteers, in which the total concentrations (free and lipoidal esters) of 24S-hydroxycholesterol and 27-hydroxycholesterol were measured, and a later independent study, in which the free forms of all three oxysterols were measured in eight other volunteers. Because the brain represents the donor and acceptor compartments for 24S- and 27-hydroxycholesterol, respectively, we also examined the possible existence of steroid gradients within the brain.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Autopsy materials from brain were obtained from a male subject who died at the age of 80 from auricular fibrillation and cardiac insufficiency and from a male subject who died at the age of 75 due to occipital infarction. This material was the same as that used in a previous study from our laboratory (3). Four different areas of each brain were analyzed: cerebellum, temporal lobe, frontal lobe, and occipital lobe.
Studies on healthy volunteers
In Study
1, blood samples for determination of the levels of 24S-hydroxycholesterol and
27-hydroxycholesterol were available from 12 healthy male subjects previously
studied in connection with brain cholesterol homeostasis (3). In that investigation, only levels of
24S-hydroxycholesterol were reported. The investigation was performed in a
fasting state. The blood samples were taken from catheters inserted
percutaneously. A thin Teflon catheter was introduced into the brachial artery
and a Cournand catheter no. 7 was introduced into a peripheral vein, with the tip
positioned in the internal jugular vein at the level of the orbita. Samples were
taken simultaneously from the vein and from the artery.
Study 2 was performed as above, but with eight healthy male volunteers aged 2135 years. Permission to carry out the two sets of experiments was obtained from the ethical committee of the local hospital.
Intravenous injection of [2H4]27-hydroxycholesterol in the rat
Two male
rats (outbred Sprague-Dawley; 150 g) were lightly anesthetised with a
solution of Hypnorm (Janssen Pharmaceuticals; Oxford, UK) in saline
(1:10; v/v). Immediately before injection, 20 µg of
[2H4]27-hydroxycholesterol dissolved in ethanol was mixed
with albumin and physiological saline, and the mixture was injected into the tail
vein. The animal was allowed to recover for
15 min before sacrifice and
organ collection as described below. The experiment was approved by the local
animal ethics committee.
Animal feeding experiment
Two
male rats (outbred Sprague-Dawley; 150 g) were fed a diet of powdered rat
chow (Lactamin R36; Vadstena, Sweden) supplemented with 0.3%
[2H6]cholesterol and 2% peanut oil prepared as described
previously (12) for 5 and 10
days, respectively. The animals were allowed free access to the chow and water
over the course of the experiment. The experiment was approved by the local
animal ethics committee.
Organ collection and lipid extraction
Animals were stunned by brief exposure to CO2 and
sacrificed by decapitation. The brain was freed from the skull, rinsed with
saline, and transferred to ice-cold saline before being extracted as previously
described (12). Briefly, tissue
was snap frozen in liquid nitrogen, mechanically pulverized, and extracted with a
40-fold excess of chloroform-methanol (2:1; v/v). Lipid extracts were
treated as previously described (13), with the exception that no internal standards were
added.
Oxysterol measurements
The oxysterols
24S-hydroxycholesterol, 27-hydroxycholesterol, and 7
-hydroxycholesterol were
analyzed by isotope dilutionmass spectrometry using deuterium-labeled
oxysterols as internal standards, as previously described (13). The m/z of the ions monitored
were as follows: 24S-hydroxycholesterol, 413.4;
[2H3]24S-hydroxycholesterol, 416.4;
27-hydroxycholesterol, 456.4;
[2H6]27-hydroxycholesterol, 462.4;
7
-hydroxycholesterol, 456.4; and
[2H6]7
-hydroxycholesterol,
462.4.
Statistics
Data are expressed as mean ±
SEM. The significance of differences between the mean arteriovenous
concentration difference of each group was tested by two-tailed paired
Student's t-test. P values of <0.05 were regarded as
significant. Calculation of percent extraction of individual oxysterols was as
follows:
![]() |
![]() |
| RESULTS |
|---|
|
|
|---|
|
Concentration of free oxysterols in internal jugular vein and brachial artery of eight healthy male volunteers (Study 2)
Because the uptake of 27-hydroxycholesterol by the brain is likely to
occur in the free form, the fractional extraction of the free steroid would be
expected to be considerably greater than that of total 27-hydroxycholesterol. As
shown in Fig. 1, the level of free
27-hydroxycholesterol was higher in the artery than in the vein in seven of the
eight subjects studied (Fig. 1). The mean concentration in the artery was 25.1 ± 1.9 ng/ml as compared with
21.9 ± 1.4 ng/ml in the vein (P = 0.06). The net extraction of
free 27-hydroxycholesterol was calculated to be 11.8 ± 4.3% (P
< 0.03). The level of free 24S-hydroxycholesterol was higher in the vein than
in the artery in all eight subjects. As expected, the arteriovenous
concentration difference of 24S-hydroxycholesterol (7.3 ± 1.5 ng/ml) was
significant (P < 0.01), and the net extraction of this steroid was
calculated to be 25.7 ± 4.9% (P < 0.001). The levels of
free 7
-hydroxycholesterol were also measured. The arteriovenous
difference (8.4 ± 9.9 ng/ml) was not significant (P =
0.43).
Assuming a flux of 450 ml plasma per minute through the brain (4, 3), the above arteriovenous differences correspond to a total daily flux of about 7 mg 24S-hydroxycholesterol from the brain into the circulation and an uptake of about 5 mg of 27-hydroxycholesterol from the circulation into the brain (calculations based on the figures for free and lipoidal sterols presented in Fig. 1).
Entry of extracerebral 27-hydroxycholesterol into the rat brain
Two complementary strategies were employed to evaluate
the possible flux of 27-hydoxycholesterol into the brain in either acute or
chronic situations. In both cases, a small but significant passage of deuterated
27-hydroxycholesterol from the circulation into the brain was observed. First,
injection of a bolus dose of [2H4]27-hydroxycholesterol
(equivalent to a 500-fold excess of the estimated total 27-hydroxycholesterol
present in the rat circulation) led to a deuterium enrichment of brain
27-hydroxycholesterol of 3.2% and 9.6%, respectively, in two separate
experiments. Similar results were obtained following the feeding of two rats with
hexadeuterated cholesterol. In this case, a deuterium enrichment of brain
27-hydroxycholesterol of 4.3% and 5.6%, respectively, was observed, with a
corresponding enrichment of brain cholesterol and brain 24S-hydroxycholesterol of
less than 1%.
Ratio of 27-hydroxycholesterol to cholesterol in gray and white matter
As shown in Table 1, the ratio of 27-hydroxycholesterol to
cholesterol was significantly higher in the white matter than in the gray matter
of four different brain regions of autopsy materials from two subjects. In marked
contrast to this, the corresponding ratio of 24S-hydroxycholesterol to
cholesterol was 4-fold higher in the gray matter than in the white
matter.
|
| DISCUSSION |
|---|
|
|
|---|
The observed net extraction of total 27-hydroxycholesterol was low, only about 5%, and subject to great interindividual variations. Because the brain does not take up cholesterol and oxysterol-containing lipoproteins, it is reasonable to assume that it is the free steroid that is crossing the bloodbrain barrier (an assumption that is in line with the current mechanistic models of sterol transfer between lipophilic compartments). In accordance with these assumptions, the net extraction of free 27-hydroxycholesterol, 12 ± 4%, was considerably higher than above. The differences in the measured extractions are likely to be a consequence of the very high activity of plasma lecithin-cholesterol acyltransferase toward side chain oxidized oxysterols (14). It should be pointed out that venous 27-hydroxycholesterol may consist of the secretion of both absorbed and internally synthesized steroid. In view of this, and of a possible secretion of metabolites of 27-hydroxycholesterol, the apparent extraction may underestimate the rate of entry of this steroid into the brain.
The net flux of 27-hydroxycholesterol from the circulation into the human brain demonstrated here is consistent with two previous findings: a) a significant flux of deuterium-labeled 27-hydroxycholesterol from the circulation into cerebrospinal fluid in a metabolic experiment performed on a healthy volunteer (10); and b) a significant correlation between levels of 27-hydroxycholesterol in circulation and cerebrospinal fluid of both control subjects and patients with different neurological diseases (11). In addition to this, we show here that a flux of 27-hydroxycholesterol from the circulation into the brain is also possible in experimental animals.
The magnitude of the flux of 27-hydroxycholesterol from the circulation into the brain of rats was low, considerably lower than in humans. This may be due to the fact that the absolute plasma levels of 27-hydroxycholesterol are markedly lower in rat than in man, only a few ng/ml as compared with about 150 ng/ml, respectively. It may be mentioned that there are great variations in levels of 27-hydroxycholesterol in the animal kingdom, from only a few ng/ml to levels of up to 250 ng/ml or more (avian species) (I. Björkhem and T. Mörner, unpublished observations).
According to the data presented here, the apparent flux of 27-hydroxycholesterol into the human brain is of a magnitude similar to the flux of 24S-hydroxycholesterol from the brain. There was, however, no significant correlation between the concentration differences of these steroids (results not shown). Furthermore, because patients with a genetic lack of CYP27A1 (cerebrotendinous xanthomatosis) have normal levels of 24S-hydroxycholesterol in the circulation (I. Björkhem, unpublished observation), it is unlikely that the efflux of 24S-hydroxycholesterol from the brain is dependent upon a corresponding uptake of 27-hydroxycholesterol.
It
should be pointed out that although the two oxysterols have essentially identical
physicochemical properties, the capacity of 27-hydroxycholesterol to pass
lipophilic membranes appears to be somewhat greater than that of
24S-hydroxycholesterol (2). In
addition, 24S-hydroxycholesterol and 27-hydroxycholesterol are potent suppressors
of cholesterol synthesis and regulators of gene expression (15, 16). However, compared with 27-hydroxycholesterol,
24S-hydroxycholesterol is a more robust activator of the nuclear receptor
LXRß, which appears to have an important role in cholesterol homeostasis in
the brain (1720). Moreover, from a metabolic point of
view, there is a marked difference between 24S-hydroxycholesterol and
27-hydroxycholesterol. Under in vitro conditions, there is little or no
metabolism of 24S-hydroxycholesterol in various preparations from neurological
tissues, whereas highly efficient systems exist for conversion of
27-hydroxycholesterol into more polar products. These include
7
,27-dihydroxycholesterol, 7
-hydroxy-3-oxo-4-cholestenoic acid, and
perhaps also chenodeoxycholic acid (2123). However, to what extent this occurs under in vivo
conditions, and how the different metabolites may be removed from the brain, are
unknown at present.
In the present work, we compared the oxysterol composition between the white and the gray matter. The concentration of 27-hydroxycholesterol was significantly lower in the cell-rich gray matter than in the white matter in the subjects studied. This was in marked contrast to the distribution of 24S-hydroxycholesterol, where the ratio of the oxysterol to the cholesterol was much higher in the gray matter than in the white matter (Table 1). It may be mentioned that according to a recent immunocytochemical study, only small amounts of CYP27A1 were observed in the white matter of normal brains, with a much more intensive staining in the gray matter (24). The difference between the distribution of the synthetic enzyme and the distribution of the oxysterol supports the contention that most of the 27-hydroxycholesterol in the brain originates from extracerebral sources. The lower levels in the gray matter may possibly reflect a dedicated metabolic activity in these regions of the brain.
An explanation for the
low levels of 27-hydroxycholesterol in the brain, particularly in the gray
matter, may be a high capacity of the brain to convert 27-hydroxycholesterol into
more polar products, in effect creating a metabolic "sink." The first
step in the metabolism of 27-hydroxycholesterol in the brain is likely to be
catalyzed by the oxysterol 7
-hydroxylase (CYP7B1), which is present at
surprisingly high levels in the brain (25). Because 7
-hydroxylated metabolites of oxysterols
may be less cytotoxic and also less inhibitory in relation to cholesterol
synthesis (2628), the high levels of CYP7B1 in the brain
may be regarded as a protective mechanism. These metabolites must, however, be
removed from the brain. Attempts are now being made in our laboratory to define
the terminal excretion products of 27-hydroxycholesterol from the human
brain.
In previous studies that examined the arteriovenous
concentration differences across the liver (3, 6), the
apparent net extraction of total 27-hydroxycholesterol was found to be similar to
that found here for the brain (3,
6). Importantly, the apparent net
extraction of more polar metabolites increased in line with increasing activity
of the steroid as a bile acid intermediate, with an apparent extraction of >40%
of 7
-hydroxy-3-oxo-4-cholestenoic acid reaching the liver. This provides
independent support for the importance of metabolic sinks in establishing and
maintaining concentration gradients. A schematic view of possible metabolic sinks
governing movement between some physiological compartments is shown in Fig. 2
.
|
| ACKNOWLEDGMENTS |
|---|
Manuscript received January 20, 2005 and in revised form February 9, 2005.
| REFERENCES |
|---|
|
|
|---|
-Hydroxylation of 27-hydroxycholesterol in
rat brain microsomes. C. R. Acad. Sci. III.
318:345
349.[Medline]
-hydroxylase
in non-hepatic cells results in liver phenotypic resistance of the low density
lipoprotein receptor to cholesterol repression. J. Biol.
Chem. 267:22695
22698.
-Hydroxylation and 3-dehydrogenation
abolish the ability of 25-hydroxycholesterol and 27-hydroxycholesterol to induce
apoptosis in thymocytes. Eur. J. Biochem.
247:129
135.[Medline]
-hydroxylation and
the ability of 25- and 27-hydroxycholesterol to suppress the activity of HMG-CoA
reductase. Biochim. Biophys. Acta.
1344:241
249.[Medline]This article has been cited by other articles:
![]() |
U. Panzenboeck, U. Andersson, M. Hansson, W. Sattler, S. Meaney, and I. Bjorkhem On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis J. Lipid Res., May 1, 2007; 48(5): 1167 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Meaney, M. Heverin, U. Panzenboeck, L. Ekstrom, M. Axelsson, U. Andersson, U. Diczfalusy, I. Pikuleva, J. Wahren, W. Sattler, et al. Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7{alpha}-hydroxy-3-oxo-4-cholestenoic acid J. Lipid Res., April 1, 2007; 48(4): 944 - 951. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |